Neal Kleiman, MD
Interventional Cardiology · Houston, TXNPI 1922038298
Payments from drug & device makers
Across 817 payments — averaging $5875.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2.7M
- Medtronic$1.6M
- Abbott$241K
- Edwards Lifesciences$145K
- Siemens Medical Solutions USA, Inc.$60K
- Bayer$17K
- plus $18K from 18 others
What the payments were for
- Consulting fees$11,56310%
- Speaking & faculty fees$45,75539%
- Travel & lodging$35,86830%
- Food & beverage$25,30221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 142 | $2,682,843 |
| Medtronic(2 entities) | 388 | $1,636,789 |
| Abbott | 125 | $240,731 |
| Edwards Lifesciences | 49 | $145,135 |
| Siemens Medical Solutions USA, Inc. | 47 | $60,023 |
| Bayer | 3 | $16,903 |
| Philips North America LLC | 13 | $11,654 |
| Daiichi Sankyo Inc. | 4 | $3,258 |
| Abiomed | 10 | $1,335 |
| AstraZeneca | 4 | $338 |
| Biotronik Inc. | 3 | $306 |
| Getinge USA Sales, LLC | 13 | $169 |
| Amgen | 2 | $131 |
| Heartflow, Inc. | 1 | $113 |
| Penumbra, Inc. | 1 | $88 |
| Tactile Systems Technology Inc | 4 | $69 |
| Cardiva Medical, Inc. | 1 | $46 |
| Novartis | 1 | $35 |
| Cardiovascular Systems Inc. | 1 | $33 |
| Jenavalve Technology, Inc. | 1 | $33 |
| BTG International Inc. | 1 | $26 |
| Teleflex LLC | 1 | $20 |
| Shockwave Medical, Inc | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$31,168
- COREVALVE EVOLUT R$19,459
- Artis Q ceiling$11,303
- US Und$10,400
- Artis icono$9,138
- Impella$1,286
- MitraClip$737
- SYNERGY$407
- AVVIGO Guidance System$367
- Mitra Clip system$273
- GENERAL VASCULAR ACCESS$271
- DRAGONFLY OPSTAR$242
- (6342) Intrasight Integrated$227
- (BQ9) Coronary IVUS$223
- COMET$222
- Xience Sierra Coronary Stent$219
- APOLLOTM$214
- BRILINTA$213
- General - Balloon Catheters$163
- HARMONY$160
How this compares
$4,800,117 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $138,446 |
| EntrestoSacubitril/Valsartan | 86 | $95,285 |
| XareltoRivaroxaban | 34 | $47,651 |
| Repatha SureclickEvolocumab | 53 | $46,590 |
| JardianceEmpagliflozin | 29 | $39,710 |
| FarxigaDapagliflozin Propanediol | 28 | $21,775 |
| Praluent PenAlirocumab | 22 | $15,958 |
| BrilintaTicagrelor | 12 | $15,358 |
| Ezetimibe | 300 | $9,438 |
| VascepaIcosapent Ethyl | 18 | $8,675 |
| Rosuvastatin Calcium | 365 | $6,450 |
| Ranolazine ErRanolazine | 55 | $6,387 |
| Eplerenone | 66 | $6,220 |
| Metoprolol Succinate | 337 | $4,976 |
| Atorvastatin Calcium | 361 | $4,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $35 | $95,28586 claims |
| Johnson & JohnsonXarelto | $17 | $47,65134 claims |
| AstraZenecaFarxiga, Brilinta | $338 | $37,13340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
- Salman ArainHouston$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.